Novolimus

Star0

DB19085InvestigationalSmall molecule

Novolimus is under investigation in clinical trial NCT04483791 (Dynamx Bioadaptor Hong Kong Registry).

Formula / weight: C₅₀H₇₇NO₁₃ · 900.16 g/mol (avg)
Also known as: 16-o-demethylrapamycin · 16-o-demethylsirolimus · 7-o-demethylrapamycin · 7-o-demethylsirolimus · Rapamycin, 7-o-demethyl-
Code names: CJ-12263 · N-929-89B

Resolves to

Compound

UNII2719UAHUA8CAS151519-50-5ChEMBLCHEMBL3544688

Structure

InChIKeyZHYGVVKSAGDVDY-QQQXYHJWSA-NSMILES

[H][C@@]12CC[C@@H](C)[C@@](O)(O1)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@]([H])(CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](O)C2)[C@H](C)C[C@@H]1CC[C@@H](O)[C@@H](C1)OC

Targets

P42345MTOR

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Novolimus, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account